Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

Ivosidenib (AG-120) is an oral, targeted agent that suppresses production of the oncometabolite 2-hydroxyglutarate via inhibition of the mutant isocitrate dehydrogenase 1 (IDH1; mIDH1) enzyme. From a phase 1 study of 258 patients with IDH1-mutant hematologic malignancies, we report results for 34 pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Roboz, Gail J., DiNardo, Courtney D., Stein, Eytan M., de Botton, Stéphane, Mims, Alice S., Prince, Gabrielle T., Altman, Jessica K., Arellano, Martha L., Donnellan, Will, Erba, Harry P., Mannis, Gabriel N., Pollyea, Daniel A., Stein, Anthony S., Uy, Geoffrey L., Watts, Justin M., Fathi, Amir T., Kantarjian, Hagop M., Tallman, Martin S., Choe, Sung, Dai, David, Fan, Bin, Wang, Hongfang, Zhang, Vickie, Yen, Katharine E., Kapsalis, Stephanie M., Hickman, Denice, Liu, Hua, Agresta, Samuel V., Wu, Bin, Attar, Eyal C., Stone, Richard M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Plenary Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7019193/
https://ncbi.nlm.nih.gov/pubmed/31841594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019002140
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados